---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-25-000003"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T02:10:40.310941+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ImmuneOnco doses first patient in Instil's IMM2510 Phase 1b/2 NSCLC trial; data in 2H 2025

## Summary
- ImmuneOnco dosed first patient in combined-chemotherapy trial for advanced NSCLC in China.
- Initial clinical data for 1L advanced NSCLC expected as early as second half of 2025.
- Instil targets initiating U.S. first-line NSCLC trial of IMM2510 plus chemo in 2H 2025, subject to regulatory approvals.
- CEO Bronson Crouch says positive data could enable a global registrational study in front-line NSCLC.

## SEC filing metadata
- accession: 0001789769-25-000003
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000003/0001789769-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000003/til-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-25-000003
- JSON: https://secwatch.observer/filing/0001789769-25-000003.json
- Plain text: https://secwatch.observer/filing/0001789769-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.